Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (The ESTxENDS Trial)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,246
- 试验地点
- 8
- 主要终点
- Continuous smoking abstinence (1)
研究概览
简要总结
Cigarette smoking is the leading cause of preventable death in Switzerland and still more than a quarter of the Swiss population smokes cigarettes. Recently, electronic nicotine delivery systems (ENDS; also called vaporizer or electronic cigarette) have become popular with smokers who want to stop smoking or reduce their exposure to inhaled chemicals since ENDS use appears to be safer than tobacco smoking. Only two rigorous randomized controlled trials (RCTs) on the efficacy of ENDS to help smokers quit have been published so far. They have promising, yet inconclusive results, as the number of included participants were small. The safety and potential adverse effects of ENDS are also largely unknown. While the aerosol the users inhale appears safe in laboratory conditions, the difference in exposure to chemicals (such as reduction in exposure to volatile organic compounds) and effects of chemicals on the body (adverse events, improved health-related outcomes and measures of oxidative stress) between smokers who quit (with or without ENDS) and those who use ENDS for a long time have not yet been assessed in an RCT.
This study will therefore test the efficacy of ENDS for cigarette smoking cessation, the safety of ENDS on adverse events and the effect of ENDS on health-related outcomes and exposure to inhaled chemicals.
The primary hypothesis of this trial is that providing cigarette smokers willing to quit smoking tobacco cigarettes with ENDS leads to a higher rate of smokers who quit cigarette smoking than only smoking cessation counseling with nicotine replacement therapy (NRT), which represents nowadays the standard of care.
For this trial, cigarette smokers motivated to quit smoking cigarettes will be included. Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants in the control group will receive smoking cessation counseling only. Participants in both groups will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
盲法说明
Statisticians and laboratory personnel will be blinded to group allocation.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Informed Consent as documented by signature
- •Persons aged 18 or older
- •Currently smoking 5 or more cigarettes a day for at least 12 months
- •Willing to try to quit smoking within the next 3 months,
- •Persons providing a valid phone number, a valid email address and/or a valid postal address.
排除标准
- •Known hypersensitivity or allergy to contents of the e-liquid
- •Participation in another study with investigational drug within the 30 days preceding the baseline visit and during the present study where interactions are to be expected
- •Women who are pregnant or breast feeding
- •Intention to become pregnant during the course of the scheduled study intervention, i.e. within the first 6-months of the study
- •Persons having used ENDS regularly in the 3 months preceding the baseline visit
- •Persons having used nicotine replacement therapy (NRT) or other medications with demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion within the 3 months preceding the baseline visit
- •Persons who cannot attend the 6- month follow-up visit for any reason
- •Cannot understand instructions delivered in person or by phone, or otherwise unable to participate in study procedures
结局指标
主要结局
Continuous smoking abstinence (1)
时间窗: 6 months post quit date
Self-report of having smoked no cigarettes from quit date, validated by urinary levels of anabasine. If anabasine is missing, validation by exhaled carbon monoxide (CO).
次要结局
- Number of cigarettes smoked per day (CPD)(baseline, target quit date, 1, 2, 4, 8 weeks and 6 months post quit date)
- Self-reported smoking abstinence allowing a 2-week'grace period'(4, 8 weeks and 6 months post quit date)
- Self-reported smoking abstinence allowing up to 5 cigarettes(1, 2, 4, 8 weeks and 6 months post quit date)
- Self-reported 7-day point prevalence abstinence(1, 2, 4, 8 weeks and 6 months post quit date)
- Validated 7-day point prevalence abstinence (1)(6 months post quit date)
- Use of any other smoking cessation products (NRT, Nicotine replacement therapy)(1, 2, 4, 8 weeks and 6 months post quit date)
- Continuous smoking abstinence (2)(6 months post quit date)
- Validated smoking abstinence allowing a 2-week'grace period' (1)(6 months post quit date)
- Validated smoking abstinence allowing a 2-week'grace period' (2)(6 months post quit date)
- Validated smoking abstinence allowing up to 5 cigarettes (2)(6 months post quit date)
- Validated 7-day point prevalence abstinence (2)(6 months post quit date)
- Nicotine dependence(baseline and 6 months post quit date)
- Validated smoking abstinence allowing up to 5 cigarettes (1)(6 months post quit date)
- Change in number of cigarettes smoked per day (CPD)(baseline, 6 months post quit date)
- Withdrawal(baseline and 6 months post quit date)
- Health-related quality of life(baseline and 6 months post quit date)
- Use of any ENDS(1, 2, 4, 8 weeks and 6 months post quit date)
- Report on most common adverse events using ENDS(1, 2, 4, 8 weeks and 6 months post quit date)